Erythropoietin receptor expression and correlation to tamoxifen response and prognosis in breast cancer
Clinical Cancer Research, ISSN: 1078-0432, Vol: 15, Issue: 17, Page: 5552-5559
2009
- 28Citations
- 17Captures
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations28
- Citation Indexes28
- 28
- CrossRef15
- Captures17
- Readers17
- 15
Article Description
Purpose: The main function of erythropoietin (EPO) is to stimulate erythropoiesis. EPO receptors (EPOR) are expressed in other cell types, including tumor cells, suggesting that the EPO/EPOR pathway governs additional cellular processes besides erythropoiesis. Recombinant EPO (rhEPO) is frequently given to anemic cancer patients, although data on clinical outcome are conflicting. In an attempt to understand these clinical data, we analyzed EPO and EPOR expression in breast cancer and evaluated EPOR as a putative prognostic and predictive marker in breast cancer patients treated with tamoxifen. Experimental Design: EPO mRNA/protein and EPOR mRNA were quantified by PCR and ELISA, respectively. Tissue microarrays containing 500 breast tumors from premenopausal women randomized to tamoxifen or no adjuvant treatment were evaluated for EPOR expression by immunohistochemistry. Predictive and prognostic information was evaluated using Kaplan-Meier curves and log-rank tests to estimate recurrence-free survival (RFS). Results: EPO and EPOR were expressed in cultured cells, and breast tumor specimens expressed EPOR at varying levels. Tamoxifen treatment significantly increased RFS in patients with estrogen receptor-positive/progesterone receptor-positive (ER/PR) tumors with low EPOR expression (P = 0.001) but had no effect on RFS in patients with tumors with high EPOR expression (P = 0.98). In the untreated cohort, RFS was significantly improved for patients with ER tumors with high EPOR expression. Conclusion: EPOR is abundantly expressed in breast cancer specimens. The fact that high expression of EPOR is related to an impaired tamoxifen response in ER/PR tumors and to improved survival in untreated patients suggests that EPOR expression in breast cancer affects tumor behavior. © 2009 American Association for Cancer Research.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=69949089786&origin=inward; http://dx.doi.org/10.1158/1078-0432.ccr-08-3014; http://www.ncbi.nlm.nih.gov/pubmed/19706814; http://clincancerres.aacrjournals.org/cgi/doi/10.1158/1078-0432.CCR-08-3014; https://syndication.highwire.org/content/doi/10.1158/1078-0432.CCR-08-3014; https://aacrjournals.org/clincancerres/article/15/17/5552/74398/Erythropoietin-Receptor-Expression-and-Correlation; https://dx.doi.org/10.1158/1078-0432.ccr-08-3014; https://clincancerres.aacrjournals.org/content/15/17/5552
American Association for Cancer Research (AACR)
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know